Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Cerebral Blood Flow Response to Different Breathing Patterns During Inspiratory Pressure Threshold Loading
Pruter, Wyatt W. , Joyner, Michael J. , Joyner, Michael J , Hughes, Morgan A , Ramsook, Andrew H

Physiology | July 1, 2025 | Volume: 40 | Issue: S1 | Pages: No page available

10.1152/physiol.2025.40.s1.0757 Get It

Introduction: Regulation of cerebral blood flow (CBF) is vital for ensuring blood supply to cerebral tissue, and studies have shown that CBF increases to match the demands of whole-body exercise. Additionally, studies have shown that an inspiratory muscle metaboreflex induced by fatiguing inspiratory work causes a decrease in blood flow to limbs and splanchnic organs, presumably redirecting blood flow to the activated inspiratory muscles. However, it is unknown if the metaboreflex response is greater when targeting the diaphragm during inspiration as opposed to using all inspiratory muscles. We aimed to determine if middle cerebral artery velocity (MCAv), a surrogate for global CBF, was affected by inspiratory muscle metaboreflex, and if so, if MCAv is affected differently when targeting diaphragmatic pressure (PTL-diaphragm; PTL di ) vs targeting mouth pressure (PTL-mouth; PTL mo ). We hypothesized that MCAv will be preserved with fatiguing inspiratory work, in both PTL di and PTL mo breathing patterns. Methods: We studied 11 (5 females) participants without any cardiorespiratory, metabolic, or musculoskeletal diseases (36±9 yrs, FEV 1 /FVC: 100±8%predicted). Each participant had gastric and esophageal balloon catheters placed to measure respiratory pressures. Blood pressure was continuously recorded via finger photoplethysmography. Transcranial doppler ultrasound continuously recorded MCAv. Participants performed breathing trials through a custom-built inspiratory pressure loading (IPTL) device, designed to open when negative pressure was generated. Each trial was comprised of 15 breaths/minute, with each breath consisting of 70% inspiration and 30% expiration. Trial 1 involved 5 minutes of PTL mo targeting 60% of their maximal inspiratory pressure, and trial 2 consisted of 5 minutes of PTL di targeting 60% transdiaphragmatic pressure. CO 2 was administered during IPTL to avoid hypocapnia. Cerebrovascular conductance index (CVCi) was calculated from MCAv. A paired t-test compared the 2 trials, deltas are calculated from end task to baseline, and data are reported as mean±SD. Results: The transdiaphragmatic pressures (PTP di ) between the two trials were different (PTL mo : 5,051±2,620, PTL di : 7,082±2,200 cmH 2 O·s/min; p=0.009). The change inMAP were not different between trials (PTL mo : 8±4, PTL di : 13±9 ΔmmHg; p=0.10). There was no difference in the change in MCAv (PTL mo : 10.07±21.51, PTL di : 9.66±22.10 Δcm/s; p=0.96) or CVCi (PTL mo : 0.03±0.23, PTL di : -0.01±0.17 Δcm/s/mmHg; p=0.55) between the two trials. Conclusion: These findings suggest that the inspiratory muscle metaboreflex does not impair CBF regulation during IPTL; this is true regardless of inspiratory muscle recruitment. Further work should focus on continuing the breathing exercises until exhaustion. NIH (HL139854); NSERC (PDF-577750-2023) This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Inhibition of CD40-TRAF6 interaction improves microvascular function and left ventricle function in a familial hypercholesterolemia swine model
Sorop, Oana , Hekkert, Maaike te Lintel, Duncker, Dirk J. , Vos, W.G., Bobí, Joaquim , Merkus, Daphne , Wentzel, Jolanda J. , Lutgens, Esther

Physiology | July 1, 2025 | Volume: 40 | Issue: S1 | Pages: No page available

10.1152/physiol.2025.40.s1.0677 Get It

CD40 signalling is involved in chronic inflammation, which is increasingly recognized as an important factor in initiation and progression of various cardiovascular diseases. Inhibition of the CD40-TRAF6 pathway was previously shown to be effective in preventing atherosclerosis and obesity in mice (Seijkens, JACC 2018, Chatzigeorgiou, PNAS 2014). In the present study we investigated the effect of CD40-TRAF6 inhibitor, compound 6877002 on left ventricular (LV) and coronary microvascular function in an adult swine model of familial hypercholesterolemia (FH). For this purpose, 10 adult male FH swine (3 years old, homozygous LDLR R84C mutation) received an atherogenic diet (10% lard and 0.75% cholesterol) for 9 months. During the last 3 months, 5 swine were subjected to treatment with the 6877002 compound (0.16 mg/kg i.v), while 5 animals received the vehicle i.v. At the end of treatment, swine were anesthetized and LV performance was studied under closed-chest conditions by pressure-volume loops constructed at baseline and during cardiac preload reduction. Subsequently, small coronary arteries (±250 μm diameter) were harvested from the LV and endothelium-dependent response to bradykinin in the presence and absence of endothelial nitric oxide (eNOS) blockade with LNAME, as well as endothelium-independent responses to the nitric oxide donor SNAP were studied in vitro. 6877002-treated animals showed a lower LV end-diastolic pressure (0±2 mmHg) as compared to vehicle-treated animals (6±1 mmHg, p≤0.05), and trends towards a reduced LV stiffness, reflected in a lower slope of the end diastolic pressure-volume relationship (sEDPVR: 0.16±0.02 mmHg/ml vs 0.20±0.01 mmHg/ml, p=0.07), and a higher ejection fraction (EF 46±2% vs 40±2%, p=0.08). Data from isolated small coronary arteries indicated that endothelium-independent vasorelaxation in response to SNAP was similar in both 6877002- and vehicle-treated animals, indicating unaltered vascular smooth smooth mucle cell responsiveness to NO. However, 6877002 treatment improved endothelium-dependent vasorelaxation to bradykinin (p≤0.05), as compared to vessels isolated from vehicle-treated animals. Moreover, eNOS blockade with LNAME blunted the endothelium-dependent vasorelaxation to bradykinin only in vessels from 6877002-treated animals, but not in those from the vehicle-treated swine, suggesting that NO bioavailability was completely lost in the vehicle-treated FH-animals, which was at least partially restored by treatment with 6877002 Conclusion: – Initation of CD40-TRAF6 pathway inhibition in adult FH swine receiving a high fat diet reduced LV end-diastolic pressure and enhanced LV passive compliance. The improved LV performance was accompanied by an amelioration of coronary microvascular endothelial dysfunction, characterized by the partial restoration of NO bioavailability. Funding: Grant 2020B008 RECONNEXT This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Digital Twin of the Stomach: Applications to Digestive Disorders and Surgery Planning
Pasricha, Pankaj J. , Kuhar, Sharun , Seo, Jung-Hee , Mittal, Rajat

Physiology | July 1, 2025 | Volume: 40 | Issue: S1 | Pages: No page available

10.1152/physiol.2025.40.s1.0672 Get It

Objective: The recent advances in computational power have enabled the use of in-silico approaches in studying physiological flows. In this study, we aim to develop a digital twin of the human stomach, StomachSim, to simulate gastric biomechanics in case of motility disorders and surgery. Methods: A physiologically realistic model of the stomach, including the antral motility, is synthesized based on in-vivo imaging data. The mixing and gastric emptying are simulated using computational fluid dynamics (CFD). Fundic accommodation, terminal antral contraction, and the phasic opening of the pyloric sphincter are incorporated into the model. The enlargement and disruption of pyloric sphincter due to pyloric intervention procedures or pyloric incompetence is also implemented. The influence of food properties (density and viscosity), motility disorders (50% reduced amplitude of antral contractions), and pyloric intervention procedures on gastric mixing, duodenogastric reflux, and solid-food trituration is investigated. The gastric emptying rate and the transpyloric pressure gradient predicted by the model were in good agreement with existing in-vivo measurements in the literature. Results: Reduced antral motility led to inefficient mixing of gastric contents and 49% lower pressure forces and 33% reduced hydrodynamic shear stresses on solid food particles. In cases with pyloric incompetence, reduced motility resulted in 66% lower duodenogastric reflux rate. When the gastric contents were of higher viscosity, the proximal stomach applied a higher pressure to achieve the same emptying rate resulting in reduced duodenogastric reflux. Higher viscosity also led to over 7 times increased shear stresses on solid food particles. Food density, on the other hand, primarily affected the transport of refluxed contents – when the gastric contents were lighter, duodenal contents entering the stomach settled along the lower antrum, and when the gastric contents were heavier, the reflux contents were transported proximally towards the esophagus. Conclusion: The digital-twin model presented in this study allows the exploration of a wide set of parameters related to gastric function. Our simulations quantify the consequences of motility disorders on gastric digestion and duodenogastric reflux. The model also reports detailed force characteristics of solid food particles undergoing trituration. StomachSim offers a novel and potentially effective modality for examining the effect of gastric conditions and gastric surgical procedures on gastric function. The authors acknowledge support from NSF award CBET 2019405. This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Leg Vascular Conductance During Fatiguing Inspiratory Muscle Work Is Not Different Between Females And Males
Pruter, Wyatt W. , Joyner, Michael J. , Joyner, Michael J , Hughes, Morgan A , Ramsook, Andrew H

Physiology | July 1, 2025 | Volume: 40 | Issue: S1 | Pages: No page available

10.1152/physiol.2025.40.s1.0601 Get It

Background: Fatiguing inspiratory muscle work can trigger the sympathetically-mediated respiratory muscle metaboreflex. Activating this reflex has been shown to increase blood pressure and heart rate while decreasing peripheral blood flow. Studies have shown females have an attenuated mean arterial pressure response (MAP) compared to males despite similar workloads to fatiguing inspiratory muscle work, suggesting females may have an attenuated respiratory muscle metaboreflex. However, the sex difference effects of respiratory muscle metaboreflex effects on resting limb vascular conductance (LVC) remains unknown. The purpose of this study was to investigate whether sex differences exist in LVC responses to fatiguing inspiratory muscle work. We hypothesize that males would exhibit a greater decrease in LVC compared to females. Methods: Eight healthy females (F; 35±11 years) and 8 healthy males (M; 31±6 years) completed the study. Participants completed a 5-minute baseline followed by a 5-minute inspiratory pressure threshold loading (IPTL) trial. The breathing pattern was set to 60% of their maximal inspiratory mouth pressure with a breathing frequency of 15 breaths/minute and an inspired duty cycle of 0.7 to activate the respiratory muscle metaboreflex. CO 2 was introduced into the inspired circuit to prevent hypocapnia. Continuous MAP (finger photoplethysmography) and heart rate (electrocardiogram) were recorded. Continuous blood velocity and diameters of the superficial femoral artery were measured using duplex ultrasonography. Leg blood flow (LBF) was calculated as the product of mean blood velocity and femoral artery cross-sectional area. LVC was calculated as LBF/mean arterial pressure. These data were averaged in 30-second segments and reported from 5-minute mark of IPTL (End-Task % of baseline). Groups were compared using Student’s t -test and analyzed using a two-way repeated-measures ANOVA. Results: Pulmonary function was within predicted ranges for all participants (FEV 1 /FVC: [F vs. M]: 100±8 vs. 100±9%predicted; P=0.919). Heart rate ([Baseline: F vs. M]: 70±13 vs. 73±8 bpm; P=0.571) and MAP (Baseline: [F vs. M]: 90±12 vs. 95±8 mmHg; P=0.378) were not different between females and males at baseline or throughout the IPTL trial (Group Main Effect: p>0.05 for both). Additionally, LBF decreased in response to IPTL but there was no difference between groups (End-Task: [F vs. M]: -31±33 vs. -21±24%baseline; Time Main Effect: P=0.012, Group Main Effect: P=0.352). When accounting for blood pressure, LVC also decreased during IPTL but was not different between females and males (End-Task: [F vs. M]: -37±30 vs. -33±24%baseline; Time Main Effect: p<0.001, Group Main Effect: P=0.655). Conclusion: These preliminary data suggest LVC decreases during a 5-minute period of fatiguing inspiratory work using IPTL; however, IPTL does not elicit variable LVC decreases between females and males. NIH (HL139854); NSERC (PDF-577750-2023) This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Heterogeneous Distribution of Mitochondria and Succinate Dehydrogenase Activity in Phrenic Motor Neurons
Hernandez-Vizcarrondo, Genesis A., Bhat, Sanjana Mahadev , Fogarty, Matthew J. , Mantilla, Carlos B. , Sieck, Gary C.

Physiology | July 1, 2025 | Volume: 40 | Issue: S1 | Pages: No page available

10.1152/physiol.2025.40.s1.0177 Get It

Neuromotor control of diaphragm muscle (DIAm) involves size-dependent recruitment of phrenic motor neurons (PhMNs). To accomplish breathing, only slow (type S) and fast, fatigue resistant (type FR) DIAm motor units are recruited. Thus, type s and FR DIAm motor units are very active in sustaining ventilation throughout life. Importantly, type S and FR DIAm motor units comprise small PhMNs that innervate type I and IIa DIAm fibers, respectively. More fatigable fast (type FF) motor units are very infrequently recruited for higher force, expulsive behaviors. Type FF DIAm motor units comprise large PhMNs that innervate type IIx/IIb DIAm fibers. Previously, we reported that compared to large PhMNs, small PhMNs have higher mitochondrial volume densities reflecting their more frequent activation. Using a quantitative histochemical technique to measure the maximum velocity of the succinate dehydrogenase reaction (SDH max ), we showed that type I and IIa DIAm fibers have higher oxidative capacity compared to type IIx/IIb fibers, which correlates with mitochondrial volume density and the more frequent activation of these muscle fibers. Accordingly, we hypothesize that the SDH max of small PhMNs is greater compared to large PhMNs. PhMNs in 6 month old, female and male Sprague Dawley rats were retrogradely identified by intrapleural injection of Alexa 647-conjugated cholera toxin B (CTB). Following retrograde CTB labeling, rats were perfused intracardially with a 0.1 M PBS, euthanized, and the C1–C6 segment of the spinal cord was dissected. Spinal cord sections were cut (40 mm) in longitudinal horizontal sections and mounted in 2-well Ibidi μ-slide plates. To measure SDH max , the sections were exposed to a solution containing 80 mM succinate (maximum substrate concentration) and 1.5 mM nitro blue tetrazolium (NBT; reaction indicator). As the SDH reaction proceeded, CTB-labeled PhMNs were imaged in 3D (Z optical slice of 0.5 μm) using an oil-immersion x60/1.4 NA objective on a Nikon Eclipse A1 laser scanning confocal system. The change in optical density (OD) was measured every 15 s over a 10-min period to measure the rate of accumulation of NBT diformazan (NBT dfz ; peak absorbance of 570 nm) in PhMNs. Using the Beer-Lambert equation, the change in OD was used to determine SDH max expressed as mmol fumarate/L cell/min. In separate experiments, following retrograde CTB labeling, mitochondria in PhMNs were labeled by transdural infusion of MitoTracker Red and imaged in 3D to determine mitochondrial volume density. Our results support a size-dependent heterogeneity in PhMN mitochondrial volume density and SDH max . We conclude that more active small PhMNs have a higher mitochondrial volume density and corresponding SDH max compared to large PhMNs. NIH grant AG44615 This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma
Vaubel, Rachael A. , Oh, Ju-Hee, Mladek, Ann C. , Pasa, Tugce I. , Gantchev, Jennifer , Waller, Katie L. , Baquer, Gerard , Stopka, Sylwia A. , Regan, Michael S. , Hossain, Md Amin , Decker, Paul A. , Kosel, Matthew , Sarkaria, Paige P., Hu, Zeng , Ott, Lauren L. , Carlson, Brett L. , Zhang, Wenqiu , Lee, Eudocia Q. , Eckel‐Passow, Jeanette E. , Elmquist, William F. , Zhang, Wenjuan , Oh, Ju-Hee , Mladek, Ann C , Pasa, Tugce I , Gantchev, Jennifer K , Waller, Katie L , Baquer, Gerard , Stopka, Sylwia A , Regan, Michael S , Hossain, Md Amin , Decker, Paul A. , Kosel, Matthew , Gupta, Shiv K , Jain, Sonia , Sarkaria, Paige P , Hu, Zeng , Ott, Lauren L , Carlson, Brett L , Bakken, Katrina K , Talele, Surabhi , Zhang, Wenqiu , Ligon, Keith L , Lee, Eudocia Q , Eckel-Passow, Jeanette E , Burgenske, Danielle M , Agar, Nathalie Y R , Elmquist, William F , Sarkaria, Jann N , Vaubel, Rachael A , Zhang, Wenjuan , Gupta, Shiv K. , Jain, Sonia , Bakken, Katrina K. , Talele, Surabhi , Burgenske, Danielle M. , Agar, Nathalie Y.R. , Sarkaria, Jann N.

Clinical Cancer Research | July 1, 2025 | Volume: 31 | Issue: 17 | Pages: 3771-3786

10.1158/1078-0432.ccr-25-0244 | PMID 40591434 Get It

Abstract Purpose: Navtemadlin is a potent small-molecule inhibitor of MDM2, which has completed a phase 0 window-of-opportunity study in glioblastoma (GBM). To optimally interpret the clinical data, a detailed analysis of navtemadlin pharmacokinetics (PK), pharmacodynamics, and efficacy was performed in GBM patient-derived xenografts (PDX). Experimental Design: Response to navtemadlin was characterized in vitro and in vivo in GBM PDXs with and without MDM2 amplification. Efficacy in vivo was integrated with measured plasma and intra-tumoral drug levels to develop a translational PK/efficacy model comparing exposure effective in PDX to exposure achieved in phase 0 patient samples. Results: In vitro, navtemadlin showed robust on-target activity in TP53–wild-type GBM. In vivo efficacy strongly correlated with MDM2 amplification status. In subcutaneous PDXs, navtemadlin significantly extended survival when dosed at 25 mg/kg in an MDM2-amplified PDX compared with 100 mg/kg in a non-amplified PDX. Central nervous system distribution was limited by blood–brain barrier efflux (Kp_brain = 0.009). In an MDM2-amplified orthotopic PDX model, navtemadlin was ineffective at 100 mg/kg; when established in mice with deficient blood–brain barrier efflux (Rag−/−Abcb1a−/−Abcg2−/−), 25 mg/kg doubled survival. A tumor PK/efficacy model was built to define target exposure for efficacy in GBM, using the effective 25 mg/kg dose. Modeled exposures exceeded this threshold in three (of 16) tumor samples from phase 0 study patients at the 240 mg dose level. Conclusions: Navtemadlin efficacy was highly dependent on adequate brain penetration. Our translational PK/efficacy model suggests that the minimum effective tumor exposures were achieved only in a minority of patients with GBM.
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares
Krueger, James G. , Sarkar, Mrinal K. , Lebwohl, Mark , Gordon, Kenneth B. , Bogle, Rachael , Cole, C. , Coon, Anthony, Burden, A. David , Zheng, Min , Mangold, Aaron R. , Anadkat, Milan J. , Barker, Jonathan N., Tang, Ming , Becker, Kolja , Delić, Denis , Thoma, Christian , Mangold, A R , Sarkar, Mrinal K , Morita, Akimichi , Wasikowski, Rachael, Langley, Richard G B , Warren, Richard Bruce , Mostaghimi, Arash , Strober, Bruce E , Barker, Jonathan N., Merola, Joseph F. , Tsoi, Lam C. , Gudjonsson, Johann E

Journal of Clinical Investigation | July 1, 2025 | Volume: 135 | Issue: 17 | Pages: No page available

10.1172/jci188530 | PMID 40591420 Get It

Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC
Akahoshi, Yu , Inamoto, Yoshihiro , Spyrou, Nikolaos , Diniz, Márcio A. , Ayuk, Francis , Choe, Hannah , Doki, Noriko , Eto, Tetsuya, Etra, Aaron , Holler, Ernst , Kawakita, Toshiro , Tanaka, Takashi , Vášová, Ingrid, Ishimaru, Fumihiko , Fukuda, Takahiro, Chen, Yi‐Bin , Nakamura, Ryotaro , Ferrara, James L.M. , Kanda, Yoshinobu , Diniz, Marcio A , Doki, Noriko , Hexner, Elizabeth , Hogan, William J , Tanaka, Takashi , Yoshihara, Satoshi , Ishimaru, Fumihiko , Chen, Yi-Bin , Kanda, Junya , Nakamura, Ryotaro , Atsuta, Yoshiko , Levine, John E , Teshima, Takanori , Akahoshi, Yu , Nakasone, Hideki , Asada, Noboru , Eto, Tetsuya , Hexner, Elizabeth O. , Hiramoto, Nobuhiro , Hogan, William J. , Kataoka, Keisuke , Tanaka, Masatsugu , Uchida, Naoyuki , Levine, John E.

Blood Advances | July 1, 2025 | Volume: 9 | Issue: 18 | Pages: 4640-4653

10.1182/bloodadvances.2025016233 | PMID 40590886 Get It

Abstract Overall response (OR) that combines complete (CR) and partial responses (PR) is the conventional end point for acute graft-versus-host disease (GVHD) trials. Because PR includes heterogeneous clinical presentations, reclassifying PR could produce a better end point. Patients in the primary treatment cohort from the Japanese Society for Transplantation and Cellular Therapy (JSTCT) were randomly divided into training and validation sets. In the training set, a classification and regression tree algorithm generated day 28 refined response (RR) criteria based on symptoms at treatment and day 28. We then evaluated RR for primary and second-line treatments, using the area under the receiver operating characteristic curve (AUC) and negative predictive value (NPV) for 6-month nonrelapse mortality as performance measures. RR considered patients with grade 0/1 at day 28 without additional treatment as responders. RR for primary treatment produced higher AUCs than OR with small improvement of NPVs in both validation sets: JSTCT (AUC, 0.73 vs 0.69 [P &lt; .001]; NPV, 92.0% vs 89.6% [P &lt; .001]) and the Mount Sinai Acute GVHD International Consortium (MAGIC; AUC, 0.71 vs 0.68 [P = .032]; NPV, 90.9% vs 89.8% [P = .009]). RR for second-line treatment produced similar AUCs but much higher NPVs than OR in both validation sets of JSTCT (AUC, 0.64 vs 0.63 [P = .775]; NPV, 74.5% vs 66.0% [P &lt; .001]) and MAGIC (AUC, 0.67 vs 0.64 [P = .105]; NPV, 86.8% vs 76.1% [P = .004]). Classifying persistent but mild skin symptoms as responses and residual lower gastrointestinal GVHD as nonresponses were major drivers in improving the prognostic performance of RR. Our externally validated day 28 RR would serve as a better end point than conventional criteria in future first- and second-line treatment trials.
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis
Muchtar, Eli , Buadi, Francis K. , Kapoor, Prashant , Dingli, David , Kourelis, Taxiarchis , Leung, Nelson , Hayman, Suzanne R. , Lacy, Martha Q. , Abdallah, Nadine , Binder, Moritz , Zanwar, Saurabh , Warsame, Rahma , Kumar, Shaji , Dispenzieri, Angela , Buadi, Francis K , Kourelis, Taxiarchis , Leung, Nelson , Lacy, Martha Q , Siddiqui, Mustaqeem A , Cook, Joselle M , Abdallah, Nadine H , Zanwar, Saurabh S , Hogan, William J , Warsame, Rahma , Kumar, Shaji K , Gertz, Morie A , Muchtar, E , Binder, Moritz , Dingli, David , Dispenzieri, Angela , Gonsalves, Wilson I. , Siddiqui, Mustaqeem , Cook, Joselle , Hogan, William J. , Rajkumar, S. Vincent , Gertz, Morie A.

Blood Advances | July 1, 2025 | Volume: 9 | Issue: 16 | Pages: 4311-4316

10.1182/bloodadvances.2025016586 | PMID 40590881 Get It

Abstract This retrospective analysis examined 15 years of autologous stem cell transplantation (ASCT) for light chain (AL) amyloidosis at the Mayo Clinic (2010-2024). We aimed to assess ASCT utilization trends, factors influencing practice changes, and current indications amid newer therapies. Four hundred and forty-one ASCTs were divided into cohort 1 (2010-2019) and cohort 2 (2020-2024), revealing a significant ASCT reduction in cohort 2 (385 vs 56, average 71% annual decrease). Cohort 2 patients were older, more likely to have relapsed/refractory disease, and had higher baseline bone marrow plasma cell burden compared to cohort 1. Pre-ASCT induction was more frequent in cohort 2 (89.3% vs 56.4%), with daratumumab (Dara)–cyclophosphamide-bortezomib-dexamethasone (CyBorD) replacing CyBorD as the predominant induction regimen. Lymphoma-based regimens were also more common in cohort 2 (15.1% vs 5.3%, P = .02). Day-100 satisfactory hematological response improved in cohort 2 (91.1% vs 72.7%, P = .001), although hematological complete response rates did not significantly differ (50.9% vs 38.8%, P = .09). In summary, there is a decrease in the utilization of ASCT in AL amyloidosis. This procedure is primarily reserved for patients with suboptimal responses, relapsed/refractory disease, lymphoplasmacytic clones (predominantly immunoglobulin M amyloidosis), or high bone marrow plasma cell burden (myeloma phenotype). This study underscores a significant shift in ASCT practice, driven by novel therapies, emphasizing more personalized management in AL amyloidosis.
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Litzow, Mark R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J. , Üstün, Celalettin , Vasu, Sumithira, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Stelljes, Matthias , Onozawa, Masahiro , Thomson, Kirsty , Chen, Caroline , Hasabou, Nahla, Rosales, Matt, Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Mendizabal, Adam , Horowitz, Mary M. , Chen, Yi‐Bin , Papadopoulos, Esperanza , Perl, Alexander E , Ustun, Celalettin , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Muffly, Lori , Kim, Hee-Je , Stelljes, Matthias , Najima, Yuho , Hill, Jason , Chen, Yi-Bin , Hamadani, Mehdi , Wingard, John R. , Ueda, Masumi , Uy, Geoffrey L. , Waller, Edmund K. , Vasu, Sumithira , Hill, Jason E. , King, Denise, Devine, Steven M.

Blood Advances | July 1, 2025 | Volume: 9 | Issue: 20 | Pages: 5123-5133

10.1182/bloodadvances.2025016306 | PMID 40590852 Get It

Abstract We conducted a post hoc analysis of data from Blood and Marrow Transplant Clinical Trials Network 1506 (MORPHO), a randomized trial of gilteritinib vs placebo as posttransplantation maintenance for patients with FLT3-ITD–mutated acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (HCT), focusing the interactions between conditioning regimen intensity, measurable residual disease (MRD), and NPM1 comutation status reported from diagnosis. Comparing FLT3-ITD MRD before and after conditioning, there was no difference between myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) in eradication or reduction of FLT3-ITD MRD. For participants who were FLT3-ITD MRD negative before HCT, there was no difference in the cumulative incidence of relapse during follow-up between those receiving MAC vs RIC. NPM1 comutation was associated with the largest magnitude of relapse-free survival benefit from post-HCT gilteritinib, and in these participants, post-HCT gilteritinib in the setting of RIC appeared to be as effective as MAC at preventing relapse. MAC appeared superior to RIC in preventing relapse only in participants who were NPM1 wild type at diagnosis and FLT3-ITD MRD positive before HCT. Our findings suggest that only a subset of patients with FLT3-ITD AML undergoing HCT may benefit from MAC and that, similar to AML therapy before HCT, the intensity of the HCT regimen should be adapted according to the molecular features of the disease. This trial was registered at www.clinicaltrials.gov as #NCT02997202.